Herriot Tabuteau Sells 19,220 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) CEO Herriot Tabuteau sold 19,220 shares of the company’s stock in a transaction dated Monday, October 6th. The stock was sold at an average price of $120.17, for a total value of $2,309,667.40. Following the completion of the transaction, the chief executive officer owned 7,229 shares of the company’s stock, valued at $868,708.93. The trade was a 72.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Herriot Tabuteau also recently made the following trade(s):

• On Tuesday, October 7th, Herriot Tabuteau sold 13,390 shares of Axsome Therapeutics stock. The shares were sold at an average price of $118.77, for a total transaction of $1,590,330.30.
• On Wednesday, October 8th, Herriot Tabuteau sold 12,774 shares of Axsome Therapeutics stock. The stock was sold at an average price of $118.84, for a total transaction of $1,518,062.16.
• On Tuesday, September 16th, Herriot Tabuteau sold 19,719 shares of Axsome Therapeutics stock. The shares were sold at an average price of $114.19, for a total transaction of $2,251,712.61.
• On Friday, September 12th, Herriot Tabuteau sold 27,907 shares of Axsome Therapeutics stock. The shares were sold at an average price of $118.96, for a total value of $3,319,816.72.
• On Monday, September 15th, Herriot Tabuteau sold 15,254 shares of Axsome Therapeutics stock. The shares were sold at an average price of $117.37, for a total value of $1,790,361.98.

Axsome Therapeutics Trading Up 3.2%

Shares of AXSM stock opened at $122.52 on Friday. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.57 and a quick ratio of 1.51. Axsome Therapeutics, Inc. has a 1 year low of $75.56 and a 1 year high of $139.13. The company has a market cap of $6.11 billion, a price-to-earnings ratio of -24.17 and a beta of 0.52. The firm has a fifty day moving average price of $116.47 and a 200-day moving average price of $109.98.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Monday, August 4th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.08. Axsome Therapeutics had a negative return on equity of 283.22% and a negative net margin of 49.88%.The company had revenue of $150.04 million for the quarter, compared to the consensus estimate of $140.02 million. As a group, equities analysts predict that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Hedge Funds Weigh In On Axsome Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of AXSM. Moors & Cabot Inc. increased its position in shares of Axsome Therapeutics by 4.5% during the second quarter. Moors & Cabot Inc. now owns 2,330 shares of the company’s stock valued at $243,000 after buying an additional 100 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of Axsome Therapeutics by 1.1% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 9,889 shares of the company’s stock valued at $1,032,000 after buying an additional 107 shares in the last quarter. Mutual of America Capital Management LLC lifted its holdings in shares of Axsome Therapeutics by 0.3% in the 1st quarter. Mutual of America Capital Management LLC now owns 39,623 shares of the company’s stock worth $4,621,000 after acquiring an additional 136 shares during the last quarter. Assetmark Inc. grew its stake in shares of Axsome Therapeutics by 13.9% during the second quarter. Assetmark Inc. now owns 1,124 shares of the company’s stock valued at $117,000 after buying an additional 137 shares during the last quarter. Finally, Profund Advisors LLC boosted its stake in shares of Axsome Therapeutics by 4.6% during the second quarter. Profund Advisors LLC now owns 4,063 shares of the company’s stock valued at $424,000 after purchasing an additional 180 shares during the period. Institutional investors and hedge funds own 81.49% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on AXSM shares. Royal Bank Of Canada lifted their target price on Axsome Therapeutics from $184.00 to $189.00 and gave the company an “outperform” rating in a research report on Tuesday, August 5th. Needham & Company LLC reiterated a “buy” rating and issued a $150.00 target price on shares of Axsome Therapeutics in a research note on Monday, August 4th. Bank of America lifted their price target on shares of Axsome Therapeutics from $173.00 to $176.00 and gave the company a “buy” rating in a research note on Tuesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Wednesday. Finally, Morgan Stanley initiated coverage on Axsome Therapeutics in a research note on Thursday, July 3rd. They set an “overweight” rating and a $190.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Axsome Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $177.93.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.